for record And years discuss we pleased a David. reported you earnings our thank quarter the we the were more years hard have starting of XXXX. quarter result few first work you, to company earnings first in we ago. The put of Thank us I'm strong revenue profitability importantly results. since everyone the a today in of as that and share joining
our the products now have Alaway generating Alkindi three revenue launches With recent Preservative of commercial and Sprinkle Free, we for us.
quarters drug holidays. start available and lead royalty a with single and up provide after Azurity or in work and is adrenocortical into the commercially our I in in the quarter sales with fully $XX an put pharmaceuticals, product Sprinkle. Alkindi we neurology us with product brought in million Azurity this our addition, for in the coming the This in franchise able we orphan the payments late quarter with of liquids today became promoted insufficiency. products. remarks treatment monetize In January future of the years It to my million $X.X of pharmaceuticals should Alkindi digit transaction as addition and will to QX were oral to transaction. the
and with reps calls Our states and to meetings. group Furthermore, have hospitals are have endocrinology sales person to XX% allowing such. for meetings. more virtual allocate conference expect a recently video But community. sales initial we targets to that than the person in seen have we in our of physicians already of pediatric These allowing through focus shifting engagements conversion and are higher person engaged resources in strategy to rates, therefore been in largely more meetings drastically their growing lead
all can states nearly and as focusing as rep efforts be so will We quickly on of conduct that open are we meetings person as and in our possible. many sales possible as that accounts
states. sales person team's that open rep person then. example, accepting the states For be territory or rotate Texas, not we states out We've is the in hands meetings, newly open in focus all Northeast would as additional open deck scheduled and targeting Florida in meetings on will the got states up helping the to whichever if have
accept clear, some obviously aren't continue which those be do are there visit and open well. to as that Just to states hospitals would visits fully we
for find find person here the Zoom point them take in over key the that calls, far Zoom more them visits more we and will really calls, precedence So is physicians. than we effective far informative
for how am strategy. stronger a implement team Zoom We United to have will types being landscape to results the very the adapt advantage make example, I to than nimble in produce of strictly proud to was states As believe rapidly able changes the quickly of States. have of the sales calls across our continuing a strategy rep this company, quickly lean we pursue and evolving these and able closed and
an process discussed we for have administrative allows through take treatment a it patients, program does and important as can last a while to even which new a patients immediately this reimbursement may the be weeks. possible. few those the two. But our worked the we filled the often the as in paperwork program implemented starter get prescriptions quickly quickstart call, think is mean for or to revenue that behind As lag month treatment We by is scripts scenes that
the will by revenue to on we continue that having received the goal many more than XXX towards of new end more I'm possible, pleased to know we scripts generating focus as to report new will we've new scripts We work continue already as and of than XXXX. and follow. XXX scripts patient that patients
Now a few words regarding EM-XXX.
Free our preservative free excited quarter looks like pleased the finally over and Preservative We've to and have allergy initial are launch retailers and Health major efforts been counter. the Bausch Bausch so it the country. sales the partner will the far the Alaway Patients with by a launched a treatment data, given success. doctors commercial available be across During product
of that we additional continue a presentations. that these availability Our vial adopt adoption month both our third month as sales Biorphen, coincide will the major and to hospitals increase is commercial market prefilled product would with grow and Sales to once to continue grow to product presentations. Biorphen phenylephrine injection. use phenylephrine more ready we believe expect with syringe we offer over dramatically
ahead into COVID delays vial a backup expect the ran and production. XXXX. have due available to vial went the we our plan vaccine to However, in government mandated capacity and for executed product But manufacturer reservation
also have In addition, on syringe product we prefilled made line to we've progress XXXX. the extension and in expect that
pipeline our to turning products. Now
We our our exciting pipeline. company for are very and period approaching a
review products three those PDUFA next under four coming We in up total the six the of dates of with FDA have a months. with
and products hope approved We with shortly. are communications and partners these regular engaged are in the FDA, launched have to very we
that additional call. Wilson? expect coming late drug Troutman development value I to Wilson the we transactions call our look high stage some remain transacting business products in with our in to the up We of turn continue before pursuit future. to pipeline the We over to financials orphan will and replenish like of With would the to additional open forward in who active through walk briefly the quarters. near
